Haemonetics Corp (HAE) · Peers
Haemonetics against the 119 other companies here in its SEC industry, Surgical & Medical Instruments & Apparatus. Each figure is the one on the company's own page; the median is the peers', and the rank is among all 120, highest first.
Measure by measure
| Measure | HAE | Peer median | Rank |
|---|---|---|---|
| Market value | $5.38B | median $243.10M | 17 of 117 |
| P/E | 55.3× | median 28.2× | 9 of 35 |
| Forward P/E | 22.3× | median 20.7× | 18 of 40 |
| EV/EBITDA | 23.8× | median 18.3× | 14 of 43 |
| P/S | 4.0× | median 3.1× | 51 of 116 |
| FCF yield | 5.4% | median -3.6% | 12 of 117 |
| Gross margin | 59.0% | median 61.0% | 61 of 115 |
| Operating margin | 11.6% | median -11.7% | 20 of 113 |
| Net margin | 7.2% | median -15.2% | 27 of 113 |
| ROIC | 6.9% | median -10.8% | 31 of 96 |
| ROE | 11.6% | median -23.5% | 22 of 107 |
| Revenue growth (4y, yearly) | 7.7% | median 14.1% | 63 of 92 |
| EPS growth (yearly) | 25.1% | median 18.4% | 8 of 20 |
| Net debt / EBITDA | 3.6× | median 2.4× | 9 of 23 |
| Current ratio | 3.7× | median 2.8× | 49 of 120 |
| Stock pay / revenue | 2.5% | median 5.4% | 80 of 117 |
| Share count change | -6.7% | median 4.4% | 106 of 109 |
Green where Haemonetics is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.
The peers, largest first
| Company | Market value | P/E | ROIC | Score |
|---|---|---|---|---|
| HAEHaemonetics Corp | $5.38B | P/E 55.3× | 6.9% | 4.8 |
| SYKStryker Corporation | $113.02B | P/E 30.3× | 12.3% | 5.8 |
| MMM3M Company | $84.97B | P/E 28.4× | 27.2% | 4.9 |
| BSXBoston Scientific Corp | $64.33B | P/E 17.5× | 8.9% | 5.9 |
| BDXBecton Dickinson and Company | $52.23B | P/E 55.5× | 5.3% | 4.9 |
| RMDResMed Inc | $34.47B | P/E 22.6× | 25.8% | 6.4 |
| DXCMDexCom Inc | $32.47B | P/E 32.5× | 5843.4% | 6.6 |
| MDLNMedline Inc. | $30.96B | P/E 157.1× | 8.1% | 5.2 |
| WSTWest Pharmaceutical Services Inc | $27.03B | P/E 47.8× | 19.5% | 5.0 |
| SOLVSolventum Corp | $14.61B | P/E 10.2× | 16.9% | 5.1 |
| BAXBaxter International Inc | $13.07B | P/E – | -2.0% | 4.7 |
| PENPenumbra Inc | $12.64B | P/E 78.7× | 16.6% | 5.5 |
| GMEDGlobus Medical | $10.30B | P/E 19.2× | 12.1% | 6.8 |
| PODDInsulet Corp | $9.79B | P/E 26.1× | 22.2% | 6.1 |
| GKOSGLAUKOS Corp | $9.72B | P/E – | -24.0% | 3.4 |
| STVNStevanato Group S.p.A. | $5.72B | P/E 36.8× | 8.7% | 4.5 |
| TFXTeleflex Inc | $5.53B | P/E – | -4.3% | 4.4 |
| MMSIMerit Medical Systems Inc | $5.33B | P/E 36.6× | 8.1% | 5.9 |
| MMEDMiniMed Group, Inc. | $4.91B | P/E – | -4.5% | 4.4 |
| HTFLHeartflow, Inc. | $4.20B | P/E – | -54.1% | 3.9 |
| ICUIICU Medical Inc/de | $4.08B | P/E 135.5× | 1.8% | 4.3 |
| IRTCiRhythm Holdings, Inc. | $3.58B | P/E – | – | 5.0 |
| ATRCAtriCure, Inc. | $2.85B | P/E 270.3× | 2.4% | 5.1 |
| UFPTUFP Technologies Inc | $2.26B | P/E 31.2× | 13.1% | 5.3 |
| INSPInspire Medical Systems, Inc. | $1.99B | P/E 14.7× | 8.5% | 6.0 |
| LMATLemaitre Vascular Inc | $1.85B | P/E 28.1× | 28.7% | 6.5 |
| NVCRNovoCure Ltd | $1.64B | P/E – | -27.8% | 4.1 |
| ATECAlphatec Holdings, Inc. | $1.62B | P/E – | -7.6% | 4.3 |
| KMTSKestra Medical Technologies, Ltd. | $1.60B | P/E – | -100.5% | 4.0 |
| SKINSkinHealth Systems Inc. | $1.37B | P/E – | -3.7% | 4.0 |
| TNDMTandem Diabetes Care Inc | $1.13B | P/E – | -4.1% | 4.0 |
| IRMDIradimed Corp | $1.13B | P/E 49.0× | 51.0% | 6.1 |
| AORTArtivion, Inc. | $1.06B | P/E – | 2.2% | 4.3 |
| IARTIntegra Lifesciences Holdings Corp | $1.03B | P/E – | 3.5% | 4.1 |
| PRCTPROCEPT BioRobotics Corp | $1.01B | P/E – | -55.1% | 5.0 |
| BVSBioventus Inc. | $942.15M | P/E 17.3× | 10.1% | 5.4 |
| SIBNSI-BONE, Inc. | $882.03M | P/E – | -12.9% | 5.2 |
| BBNXBeta Bionics, Inc. | $735.58M | P/E – | -86.4% | 4.9 |
| MDXGMiMedx Group Inc | $645.72M | P/E 103.5× | 6.9% | 5.3 |
| KIDSOrthopediatrics Corp | $573.11M | P/E – | -5.8% | 5.0 |
| TCMDTactile Systems Technology Inc | $510.13M | P/E 20.5× | 18.0% | 6.9 |
And 79 smaller ones.
The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.